This Could Be Another Blockbuster Indication for AstraZeneca
Recently, AstraZeneca (NASDAQ: AZN) announced what could be very positive regulatory news for one of its rare disease drugs. The pharma stock informed shareholders that the U.S. Food and Drug Administration (FDA) accepted the regulatory submission under priority review for Ultomiris to treat adults diagnosed with the rare condition called generalized myasthenia gravis (gMG). According to AstraZeneca, gMG is an autoimmune disease, which damages the connection point between the nerve cells and the muscles that they control.
